(Bloomberg) -- Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of its prostate cancer drug, a setback that could scuttle ...

Pfizer also has experienced multiple setbacks in its attempts to develop ... Nurtec ODT for migraine and Xtandi for prostate cancer. Adjusted earnings for 2024 will be $2.75 to $2.95 a share ...

In its latest setback, Merck has announced ... in combination with Astellas/Pfizer’s Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) – its last remaining ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside Xtandi, reduced prostate cancer progression by 49%. The data ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of HRR mutation status TALZENNA + XTANDI improved median OS by almost 9 months in unselected patients (Cohort 1 ...

On the regulatory front this year, a Pfizer spokesperson said the company anticipates three regulatory decisions in prostate cancer, colorectal cancer and non-Hodgkin lymphoma, as well as seven Phase ...

Why are Genentech’s cancer researchers concerned about the direction of the company? What led Pfizer to pull its sickle ... joins us to discuss the recent setbacks and wins in oncology R&D ...

cervical and prostate cancers. “At Pfizer, we partner across the oncology community to meet the needs of people with cancer and help everyone have access to quality cancer care,” said Jeffrey ...

compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. Also Read: Pfizer ...